FDA Grants Full Approval for COVID-19 Pill Paxlovid

Pfizer is authorized to sell the drug in the United States.

The Food and Drug Administration (FDA) has granted Pfizer’s drug Paxlovid full authorization for use in the United States, clearing the way for sales of the COVID-19 treatment after President Biden’s administration runs low on free doses. 

The oral antiviral drug was originally cleared for emergency use in late 2021. President Biden’s administration has thus far distributed 14 million treatment courses to pharmacies across the country. 

In reviewing Paxlovid during the approval process, FDA advisors were concerned that patients using the drug could experience a COVID-19 rebound after treatment completion. Additional data collected by both the FDA and Pfizer eased those concerns.

As the Lord Leads, Pray with Us…

  • For Commissioner Califf as he oversees the FDA’s prioritization and review of treatments and therapies.
  • For FDA officials as they assess the benefits and downsides of various medications submitted for approval.

Sources: Reuters, Food and Drug Administration


Back to top